• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Sulfated disaccharides for the treatment of neuropathic pain. The present invention relates to the use of sulphated disaccharides of formula (1) for the treatment of neuropathic pain. The present invention also relates to a pharmaceutical composition comprising the compound of formula (1) and at least one pharmaceutically acceptable excipient for use in the treatment of neuropathic pain. The compounds of formula (1) were effective in various experimental models of neuropathic pain, so that said compounds can be used effectively for the treatment of various types of neuropathic pain and their clinical manifestations, for example, mechanical allodynia or allodynia to the cold. (Machine-translation by Google Translate, not legally binding)
    公开号:ES2684097A1
    申请号:ES201730458
    申请日:2017-03-29
    公开日:2018-10-01
    发明作者:Josep Vergés Milano；Eulàlia MONTELL BONAVENTURA；Ramon RUHÍ ROURA；Carlos Raúl Aláez Versón；Antonio García García；Manuela García López；Juan Fernando PADÍN NOGUEIRA；Marcos MAROTO PÉREZ；Javier EGEA MÁIQUEZ
    申请人:Fundacion Teofilo Hernando；Fund Teofilo Hernando；Bioiberica SA；Universidad Autonoma de Madrid；
    IPC主号:
    专利说明:

    DISULATIZES SULFATED FOR THE TREATMENT OF NEUROPATHIC PAIN
    5 Field of techniqueThe present invention relates to the pharmacotherapy of pain, and particularly of the pain ofneuropathic type
    State of the art
    10 Pain is considered one of the main current public health problems, due to the important socio-economic repercussions linked to this pathology. Various studies show that chronic pain, of moderate to severe intensity, affects approximately 20% of the adult population in Europe and has a serious impact on the quality of life of affected individuals; these studies also show that
    15 a high proportion of patients perceive that existing treatments do not provide adequate pain control, as described, for example, in the article Breivik et al., Survey of chronic pain in Europe: Prevalence, impact on daily life and treatment, Eur. J. Pain, 2006, 10, 287-333.
    20 Usually there are two types of pain, nociceptive pain and neuropathic pain. Nociceptive pain usually has its cause in an injury or damage to a tissue, which in turn triggers a stimulus of pain receptors, usually of limited duration, and can be considered as an alarm and defense system, which allows the presence to be detected. of damage to the organism.
    25 In contrast, neuropathic pain originates from a malfunction of the nerve pathways that transmit pain information, and is defined as pain originating as a direct consequence of an injury or disease that affects the somatosensory system (Treede et al. ., Neuropathic pain: redefinition and a grading system for
    30 clinical and research purposes, Neurology, 2008, 70, 1630-5).
    Neuropathic pain can be classified, according to the place where it originates, in peripheral neuropathic pain, when it is due to an injury or dysfunction of the peripheral nervous system, and central neuropathic pain, when its origin is in an injury or dysfunction of the
    35 central nervous system.


    Neuropathic pain is also usually classified according to the cause that causes it, so, for example, it is usually distinguished between post-herpetic neuralgia, diabetic neuropathy, HIV-associated neuropathy, post-chemotherapy neuropathy, trigeminal neuralgia, post-surgical neuralgia, pain post-stroke, due to multiple sclerosis, spinal cord injury, or pain associated with the phantom limb, among others.
    In addition, some studies of the state of the art conclude that pathologies such as rheumatoid arthritis or osteoarthritis, traditionally associated exclusively with pain of nociceptive type of inflammatory origin, often present pain of neuropathic origin, as described, for example, in articles Dimitroulas et al., Neuropathic pain in osteoarthritis: a review of pathophysiological mechanisms and implications for treatment, Semin. Arthritis Rheum., 2014, 44 (2), 145-54; and Christensen et al., Non-nociceptive pain in rheumatoid arthritis is frequent and affects disease activity estimation: cross-sectional data from the FRAME study, Scand. J. Rheumatol., 2016 (DOI: 10.3109 / 03009742.2016.1139174). This proportion of patients with osteoarthritis who present with neuropathic pain reaches 50% in patients with the disease who had undergone knee surgery or had gone to rehabilitation pointing to a correlation between the development of the disease and the appearance of neuropathic pain according to the article
    Oteo-Álvaro et al., High prevalence of neuropathic pain features in patients with knee osteoarthritis: A cross-sectional study, Pain Pract., 2015, 15 (7), 618-26.
    Likewise, within the different manifestations of fibromyalgia, the presence of neuropathic pain has been detected, and some studies demonstrate the existence of common factors, such as sensory perceptions, between patients with neuropathic pain and those with fibromyalgia , as described, for example, in the article Momi et al., Neuropathic pain as part of chronic widespread pain: environmental and genetic influences, Pain, 2015, 156 (10), 2100-6, or in Koroschetz et al. , Fibromyalgia and neuropathic pain -differences and similarities. A comparison of 3057 patients with diabetic painful neuropathy and fibromyalgia, BMC Neurol., 2011, 11:55. That is why fibromyalgia is treated with the same medications that are used in the treatment of neuropathic pain. In fact, the first medication specifically approved to treat fibromyalgia in the United States. was Lyrica® (pregabalin) in 2007, three years after obtaining the marketing authorization with the indication of pain treatment


    Neuropathic associated with peripheral diabetic neuropathy or postherpetic neuropathic pain.
    Recent studies indicate that neuropathic pain affects 7-8% of the population, and it is estimated that this proportion could increase in the future, among other factors, due to the increasing incidence of diabetes and the improvement of cancer survival, as described, for example, in the article Bennett DL, Informed drug choices for neuropathic pain, Lancet Neurol., 2015, 14, 129-30.
    Among the drugs of first choice for the treatment of neuropathic pain are some antiepileptic medications such as gabapentin or pregabalin; tricyclic antidepressants, such as amitriptyline, imipramine or clomipramine; or serotonin and noradrenaline reuptake inhibitors, such as duloxetine and venlafaxine. However, these drugs provide only modest efficacy in the treatment of neuropathic pain, very variable depending on the type of specific pain (Gilron et al., Neuropathic pain: principles of diagnosis and treatment, Mayo Clin. Proc., 2015, 90 , 532-545).
    Numerous publications on the state of the art coincide in considering that the therapeutic arsenal currently available for the treatment of neuropathic pain is reduced and of limited efficacy, so there is a need to develop new alternatives, as highlighted in the article Sałat et al. ., New investigational drugs for the treatment of neuropathic pain, Expert Opin. Investig. Drugs, 2014, 23, 1093-104, in which some of the new compounds currently under development for the treatment of neuropathic pain are reviewed, such as some selective voltage-dependent sodium channel inhibitors of the Nav1.7 type , such as raxatrigine (CNV1014802), funapide (XEN402) or PF-05089771; antagonists of calcium channels type N or type T, such as products Z160 or Z944; angiotensin II receptor inhibitors type AT2, such as the product EMA401; or nerve growth factor (NGF) inhibitors, for example, tanezumab.
    Thus, in view of its high prevalence, its great impact on the quality of life of patients, and the low effectiveness of current treatments, there is still a need for new drugs that are effective for the treatment of neuropathic pain. ,


    that contribute to increase the available therapeutic arsenal and allow a better control of said pathology.
    Object of the invention
    The object of the present invention is the use of a disulphated disaccharide of formula (I) for the preparation of a medicament for the treatment of neuropathic pain.
    Another aspect of the invention is the use of a pharmaceutical composition comprising a disaccharide of formula (I) and at least one pharmaceutically acceptable excipient for the preparation of a medicament for the treatment of neuropathic pain.
    Description of the figures
    Figure 1 Figure 1 is a bar chart depicting the results obtained with compound Ic and with gabapentin in an experimental model of mechanical allodynia induced in mice by intraplantar injection of capsaicin (Example 1). In the ordinate axis the percentage of allodynia is represented and in the abscissa axis the various treatments performed are represented in bars. The first bar (Ctrl) corresponds to the control group, that is, mice without treatment and without induction of allodynia. The second bar (Ic-0) corresponds to animals with allodynia induced by capsaicin injection, and without pharmacological treatment. The rest of the bars correspond to animals with allodynia induced by capsaicin injection, subjected to different oral treatments: 3 mg / Kg of compound Ic (Ic-3), 10 mg / Kg of compound Ic (Ic-10), 30 mg / kg of compound Ic (Ic-30), and 40 mg / kg of gabapentin (Gab). Data are means ± SEM of at least 10 animals per experimental group (*** p <0.001 ANOVA and Dunett test).
    Figure 2 Figure 2 is a bar chart depicting the results obtained with compound Ic and with gabapentin in an experimental model of mechanical allodynia induced in rats by chronic sciatic nerve ligation (Example 2). In the ordinate axis, half of the threshold force that is necessary to apply to cause the removal of the leg (50% pain threshold, in grams, g) is represented and in the axis of abscissa the various groups are represented in bars and treatments performed. The first bar (Ctrl) corresponds to the control group of animals without allodynia, that is, not undergoing surgery, and without any treatment. The second bar (Ic-0) corresponds to animals with allodynia induced by


    ligation of the sciatic nerve, without pharmacological treatment. The rest of the bars correspond to animals with allodynia induced by sciatic nerve ligation, subjected to different oral treatments: 40 mg / kg of gabapentin (Gab), 3 mg / kg of compound Ic (Ic-3), 30 mg / Kg of compound Ic (Ic-30), and 60 mg / Kg of compound Ic (Ic-60). Data are means ± SEM of at least 6 animals per experimental group (*** p <0.001 compared to the Ic-0 group; $$$ p <0.001 compared to the Ctrl group; one-way ANOVA followed by post-test Tukey's hoc).
    Figure 3 Figure 3 represents the results obtained with compound Ic, administered orally at different doses, and with the comparator gabapentin (Gab), in the experimental model of mechanical allodynia induced in rats by chronic ligation of the sciatic nerve (Example 2 ). In the ordinate axis, half of the threshold force that is necessary to apply to cause the removal of the leg (50% pain threshold, in grams, g) is represented, while the elapsed time is represented in the abscissa axis ( in minutes) from the administration of each drug. Empty circles represent animals treated with 40 mg / kg of gabapentin (positive control), solid circles represent animals treated with 120 mg / kg of compound Ic, triangles represent animals treated with 60 mg / kg of compound Ic and inverted triangles represent animals treated with 30 mg / kg of compound Ic. Data are means ± SEM of at least 7 animals per experimental group.
    Figure 4 Figure 4 represents the results obtained with compound Ic in an experimental model of mouse-induced allodynia by injection of paclitaxel chemotherapeutic agent (Example 3). In the ordinate axis the threshold force that is necessary to apply to cause the removal of the animal's leg is represented, expressed as a percentage with respect to the control group, consisting of animals in which no allodynia was induced, and in the abscissa axis the various groups and treatments performed are represented: Ctrl (control group, without induction of allodynia), A (baseline measurement performed on animals with paclitaxel-induced allodynia, before administering the subsequent treatment), Ic-0 (without treatment, only saline was administered), Ic-7.5 (animals treated with 7.5 mg / Kg of compound Ic), Ic-15 (animals treated with 15 mg / Kg of compound Ic) and Ic-30 (animals treated with 30 mg / kg of compound Ic). Data are means ± SEM of at least 7 animals per group


    experimental (*** p <0.001, ** p <0.01; compared to the Ctrl group, one-way ANOVA and Dunnett post-hoc test).
    Figure 5 Figure 5 represents the results obtained with compound Ic in an experimental model of mouse-induced allodynia by injection of paclitaxel (Example 3). A daily dose of Ic was administered for 5 consecutive days, in co-administration with paclitaxel. In the ordinate axis the threshold force that is necessary to apply to cause the removal of the animal's leg (in grams, g) is represented and in the abscissa axis the various groups and treatments performed are represented. In the first pair of bars the animals without any treatment (Ctrl) are compared with those that received paclitaxel together with saline, that is, they did not receive treatment with the compound Ic (Tax + Ic-0). In the second pair of bars the control group (Ctrl) is compared with the group of animals that were treated together with paclitaxel and 30 mg / Kg of the compound Ic (Tax + Ic-30). Data are means ± SEM of at least 7 animals per experimental group (*** p <0.001 compared to the Ctrl group, t-Student test).
    Figure 6 Figure 6 represents the results obtained with compound Ic in an experimental mouse model of cold allodynia induced by subcutaneous injection of carrageenan (Example 4). Cold sensitivity was quantified by administering a drop of acetone on the plantar surface of the hind legs and subsequently measuring the licking time of the leg by the animals. In the ordinate axis the leg licking time is represented (in seconds) and in the abscissa axis the different treatments are represented. The first pair of bars corresponds to the group of control animals (Ctrl), without pharmacological treatment, while the second pair of bars corresponds to the group of animals treated with 60 mg / Kg of the compound Ic (Ic-60). In each group, the bar on the left (striped) represents the test result referring to the carragenin-sensitized hind leg (ipsilateral) and the bar on the right represents the test result referring to the non-sensitized (contralateral) back leg. Data are means ± SEM of at least 7 animals per experimental group (** p <0.01 compared to white Ctrl bar, two-way paired t-test; ### p <0.001 compared to the gray Ctrl bar , two-way unpaired t-test).
    Figure 7


    Figure 7 is a bar chart depicting the results obtained with compound Ic in an experimental model in mechanical allodynia rat caused by diabetes induced by streptozotocin injection (Example 5). In the ordinate axis, half of the threshold force that is necessary to apply to cause the removal of the leg (50% pain threshold, in grams, g) is represented and in the axis of abscissa the various groups are represented in bars and treatments performed. From left to right, the first bar represents the threshold pain value of animals before starting the diabetes induction protocol. In the next two bars, the one with vertical lines corresponds to the 25-day value of the protocol before the administration of the compound, and the one with horizontal stripes 10 the value of the experimental group after the administration of the saline on the same day of the protocol. Then, in the following three bars, in order of increasing gray intensity the values of 50% threshold force are represented before removing the leg of 3 doses of compound Ic: 3, 10 and 30 mg / kg. Finally, the white bar represents the value obtained after the administration of the gabapentin control drug at the dose of 40
    15 mg / kg In all cases, the data are means ± SEM of between 7 and 10 animals per experimental group (** p <0.01. *** p <0.001 compared to the group of animals administered with saline; gray bar with horizontal stripes. Two-way unpaired T-test).
    Detailed description of the invention
    The object of the present invention is the use of a compound of formula (I):
    wherein: -R1 is selected from hydrogen, linear or branched C1-C4 alkyl, phenylalkyl of less than 10 carbon atoms and COCH3; 25 -R2 is selected from hydrogen, COCH3 and SO3Y; -R3 is selected from hydrogen, linear or branched C1-C4 alkyl, phenylalkyl of
    less than 10 carbon atoms, COCH3 and COPh, where Ph is phenyl; -G is selected from COOR4 and COOY; -A and B are selected, independently from each other, from hydrogen, SO3H, SO3Y
    30 and COCH3; where necessarily or A or B is either SO3H, or SO3Y,


    R4 is selected from hydrogen, C1-C2 alkyl and arylalkyl of less than 16 carbon atoms, and Y is an organic or inorganic cation;
    or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a5 medication for the treatment of neuropathic pain.
    Alternatively, the object of the present invention can be formulated as the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of neuropathic pain.
    Alternatively, the object of the present invention can also be formulated as a method for treating neuropathic pain in a subject in need thereof comprising the administration of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof. . Typically, a therapeutically effective amount of the
    15 compound of formula (I).
    The disaccharides represented by formula (I) had previously been described in the state of the art in relation to the treatment of osteoarthritis, or of diseases or injuries related to tendons, ligaments or bones, and also by their activity
    20 neuroprotective due to inhibition the production of reactive oxygen species.
    The authors of the present invention have found that, surprisingly, the disaccharides of formula (I) turn out to be remarkably effective for the treatment of neuropathic pain, as experimental, specific and well-proven models were demonstrated in a series
    25 representative for said pathology.
    Compound of formula (I) The compound of formula (I) is a disaccharide with β (1 → 3) linkages between glucuronic acid, or a derivative thereof, and a glucosamine derivative, and has at least
    A sulfate group in the C-4 and / or C-6 position of the glucosamine ring.
    The disaccharides of formula (I) are described in European patent application EP1300411-A1, in which methods for their preparation are provided. In said document, the disaccharides of formula (I) are proposed as an alternative to the use of hyaluronic acid
    35 for the treatment of osteoarthritis and inflammation.


    Additionally, the use of disaccharides of formula (I) for the treatment of diseases or injuries of tendons, ligaments or bones, as described in the international patent application WO2008 / 151898-A1, as well as its use as neuroprotectors and in the treatment of neurodegenerative and / or neurovascular diseases, due to their ability to reduce the formation of reactive oxygen species, protecting against cell death induced by oxidative stress and oxygen and glucose deprivation, as described in international patent application WO2011 / 080203-A1. This latter document also provides an alternative method for the preparation of the compounds of formula (I).
    In the definition of the compound of formula (I), a linear or branched C1-C4 alkyl group includes, as is well known in the art, the following alkyl groups: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec -butyl and tert-butyl; a C1-C2 alkyl group includes methyl and ethyl groups; a phenylalkyl group of less than 10 carbon atoms refers to a alk-Ph group where alk represents a linear or branched alkylene group, and Ph represents a phenyl group, wherein the total number of carbon atoms in the group - alk-Ph is less than 10; an arylalkyl group of less than 16 carbon atoms refers to a group -alk-Ar in which alk represents a linear or branched alkylene group, and Ar represents an unsubstituted, monocyclic or polycyclic aromatic carbocycle, and wherein the total number of carbon atoms of the –alk-Ar group is less than 16; And it is an organic or inorganic cation, that is, Y is chosen from an inorganic cation, for example, from an alkali metal, typically lithium, sodium or potassium, and an organic cation, for example, an ammonium group or an alkylammonium group.
    The compound of formula (I) has an anomeric carbon in its structure, which is represented by the wavy bond in the figure. The use according to the present invention includes the compound of formula (I) in its two anomeric forms α and β, as well as mixtures thereof.
    In a preferred embodiment, the use according to the present invention refers to a compound
    of formula (I), as defined above, where:
    - R1 is selected from hydrogen and linear C1-C4 alkyl, and
    - G is selected from –COOR4 and –COOY, where R4 is hydrogen or C1-C2 alkyl
    and Y is an inorganic cation, preferably the sodium cation.


    In a more preferred embodiment the compound of formula (I) is one in which R1 is hydrogen, R2 is -COCH3 and R3 is hydrogen. In another equally preferred embodiment, R1 is methyl, R2 is -COCH3 and R3 is hydrogen.
    In a particularly preferred embodiment, the compound of formula (I) is that in which A is hydrogen, B is -SO3Y and G is -COOY, where Y is an inorganic cation, preferably sodium. In another equally preferred embodiment, A is -SO3Y, B is hydrogen, and G is -COOY, where Y is an inorganic cation, preferably sodium. In another equally preferred embodiment A and B are –SO3Y and G is –COOY, where Y is a
    10 inorganic cation, preferably sodium.
    In an even more preferred embodiment of the use according to the present invention, the compound of formula (I) is selected from the group consisting of the following compounds:
    In a particularly preferred embodiment of the use according to the present invention, the compound of formula (I) is as follows:


    This compound (trisodium salt of 2-acetamido-2-deoxy-3-O- (β-D-glucopyranosyl uronic acid) -4,6-di-O-sulfo-α-D-glucopyranoside is called a compound Ic in the 5 examples.
    Treatment of neuropathic pain Neuropathic pain refers, as is well known by the person skilled in the art, to pain caused by a dysfunction of the nervous system, as a direct consequence of
    10 lesion or disease that affects the somatosensory system.
    The types of neuropathic pain that can be treated with the compounds of formula (I), according to the use of the present invention, are, for example, diabetic neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathy, HIV-associated neuropathy, 15 neuropathy associated with rheumatoid arthritis, neuropathy associated with osteoarthritis, neuropathy associated with fibromyalgia, various craniofacial neuralgia, such as trigeminal neuralgia, glossopharyngeal neuralgia, sphenopalatine ganglion neuralgia, vidian neuralgia, persistent idiopathic facial pain or primary atypical facial neuralgia, for example ; pain associated with the phantom limb, post-stroke cerebral vascular pain, post pain syndrome
    20 surgery, pain due to multiple sclerosis or pain due to spinal cord injury, among others.
    The most common symptoms of neuropathic pain are persistent stabbing, burning, burning or burning pain, with lancinating crises, dysesthesia and paraesthesia. Among the most characteristic clinical manifestations of neuropathic pain are allodynia and hyperalgesia, both related to hypersensitivity to external stimuli. Allodynia refers to the perception as painful of stimuli that normally do not cause pain, while hyperalgesia is defined as an increased response to a modestly painful stimulus. It is usually distinguished between thermal allodynia (heat
    or cold) and mechanical allodynia. Cold allodynia, for example, is characterized by a
    Exaggerated sensitivity to cold that leads to pain at temperatures that, under normal conditions, are perceived as innocuously cool.


    The efficacy of the compounds of formula (I), in particular of the compound Ic, was tested for the treatment of neuropathic pain, using various experimental models representative of said pathology. Surprisingly, it was observed that compound Ic is remarkably effective in the treatment and / or prevention of neuropathic pain symptoms in all models tested.
    Thus, in Example 1 an experimental trial is described in mice of mechanical allodynia induced by intraplantar injection of capsaicin, according to the model described in the article Entrena et al., Antagonism by haloperidol and its metabolites of mechanical hypersensitivity induced by intraplantar capsaicin in mice : role of sigma-1 receptors, Psychopharmacology, 2009, 205, 21-33. This assay is based on the induction of hypersensitivity (allodynia) in mice by injecting capsaicin in the right hind leg. Allodynia is quantified by measuring the decrease in latency time in hypersensitized mice until the leg is removed, by applying a mechanical stimulus on it. As described in said example, compound Ic shows a remarkable effect on the reversal of allodynia in this model (Figure 1).
    An experimental trial of mechanical allodynia induced in rats by chronic sciatic nerve ligation is described in Example 2, according to the model described in the article Decosterd et al., Spared nerve injury: an animal model of persistent peripheral neuropathic pain, Pain, 2000 , 149-158. This model is based on causing mechanical allodynia in rats by ligating two of the three branches of the sciatic nerve (tibial and peroneal), leaving the sural branch intact. The allodynia thus induced is quantified by the observed decrease in the threshold force that is necessary to apply to produce the removal of the leg in the animals subjected to ligation. As described in said example, it is observed that the administration of different doses of compound Ic is effective in reversing the allodynia induced in said model (Figures 1 and 2).
    In Example 3 an experimental mouse model based on the induction of allodynia by intraperitoneal injection of paclitaxel is used, as described in the articles Smith et al., Paclitaxel-induced neuropahtic hypersensitivity in mice: responses in 10 inbred mouse strains, Life Sci., 2014, 2593-2604 and Palomano et al., Chemotherapy-evoked painful peripheral neuropathy, Pain Med., 2001, 2 (1), 8-14. In alternative tests, compound Ic was subsequently administered to induction of allodynia by paclitaxel, or was administered


    in conjunction with said chemotherapy. It is observed that compound Ic is effective both to reverse paclitaxel-induced allodynia (Figure 4), and to prevent its development when co-administered with paclitaxel (Figure 5).
    In Example 4 an experimental model of cold-induced allodynia in mice is used by subcutaneous injection of carrageenan, as described in the article Choi et al., Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain, Pain , 1994, 59 (3), 369-376. This test is based on causing cold allodynia in mice by subcutaneous injection of carrageenan on the plantar surface of one of the animal's hind legs, and subsequently measuring the sensitivity to cold by applying acetone on the plantar surface of both hind legs. : the ipsilateral (the same one where the carrageenan was injected) and the contralateral (the back leg not sensitized). Cold sensitivity is quantified by measuring the licking time of the paw by the animals for 5 minutes after the application of acetone. As described in said example, compound Ic is effective in reversing allodynia to cold according to this model (Figure 6).
    An experimental trial of mechanical allodynia in rats for diabetes induced by intraperitoneal injection of streptozotocin is described in Example 5, based on the model described in the article Courteix et al., Streptozocin-induced diabetic rats: behavioral evidence for a model of chronic pain , Pain, 1993, 81-88. This model is based on causing mechanical allodynia in rats by induction of diabetes by intraperitoneal injection of streptozotocin. It is observed that the administration of different doses of compound Ic is effective in reversing diabetes-induced allodynia, as quantified by the statistically significant increase observed in the treated animals, of the threshold force that is necessary to apply to produce the removal of the paw. in animals (Figure 7).
    The treatment according to the present invention is indicated to be applied to any mammalian animal that requires such treatment, preferably humans.
    Within the framework of the present invention, the term "treatment" includes treatment for therapeutic purposes, that is, aimed at eliminating or reducing the symptoms of neuropathic pain, when these have already manifested, and also includes treatment for preventive purposes or prophylactic, that is, aimed at preventing or delaying the onset of neuropathic pain symptoms before they appear, in patients suffering


    diseases or present clinical situations conducive to the development of said pathology, for example, in cancer patients undergoing chemotherapy.
    In one embodiment, the use according to the present invention specifically refers to reversing5 or prevent the symptoms of mechanical allodynia or cold allodynia.
    In one embodiment, the use according to the present invention relates to the treatment of diabetic neuropathy. Diabetic neuropathy has its origin in a peripheral nerve injury that occurs in diabetic people, and that is related to the damage
    10 microvascular produced by hyperglycemia and insulin failure to control plasma glucose levels.
    In another embodiment, the use according to the present invention relates to the treatment of post-herpetic neuralgia. Post-herpetic neuralgia is a complication associated with
    15 shingles, characterized by a continuous pain along a nerve and its branches, which persists after the eruption of herpes disappears.
    In another embodiment, the use according to the present invention relates to the treatment of chemotherapy-induced neuropathy. Chemotherapy-induced peripheral neuropathy
    20 is considered the most frequent neurological complication of cancer treatment, and is mainly associated with treatment with the anti-cancer drugs vincristine, paclitaxel, docetaxel, or those based on platinum (cisplatin and oxaliplatin), among others.
    In another embodiment, the use according to the present invention relates to the treatment of the
    25 neuropathy associated with HIV (human acquired immunodeficiency virus). HIV-associated neuropathy is a common complication in patients with HIV that originates from nerve damage that can be caused by both the virus and some HIV treatments, and that usually causes pain, numbness, burning, or itching in the limbs
    In another embodiment, the use according to the present invention relates to the treatment of neuropathy associated with rheumatoid arthritis. This type of neuropathic pain refers to the extra-articular neurological manifestations that occur in some patients with rheumatoid arthritis, and that may involve both the central nervous system and the
    35 peripheral.


    In another embodiment, the use according to the present invention relates to the treatment of neuropathy associated with osteoarthritis, related to the treatment of neuropathic pain manifested by some patients suffering from osteoarthritis.
    In another embodiment, the use according to the present invention relates to the treatment of neuropathy associated with fibromyalgia. This use of the invention relates to the treatment of pain manifestations of neuropathic origin present in patients with fibromyalgia.
    In another embodiment, the use according to the present invention relates to the treatment of trigeminal neuralgia. Trigeminal neuralgia is defined as a neuropathic disorder of the trigeminal nerve that causes a stabbing pain in parts of the face, and may have its origin in a pressure exerted on the trigeminal nerve because of a tumor, or by a blood vessel, due to trauma, or it may be associated with multiple sclerosis.
    In another embodiment, the use according to the present invention relates to the treatment of glossopharyngeal neuralgia. Glossopharyngeal neuralgia is a neuralgia that affects the glossopharyngeal nerve and is characterized by severe pain located around the throat and ear, and that can be triggered by swallowing, chewing, clearing or speaking.
    In another embodiment, the use according to the present invention relates to the treatment of pain associated with the phantom limb. This type of neuropathic pain refers to the presence of painful sensations in an absent limb, after an amputation.
    Pharmaceutical compositions Another aspect of the present invention is the use of a pharmaceutical composition comprising a compound of formula (I), as defined above, or a salt
    or a pharmaceutically acceptable solvate thereof, and at least one pharmaceutically acceptable excipient, for the preparation of a medicament for the treatment of neuropathic pain.
    Or formulated in another way, another aspect of the invention is a pharmaceutical composition comprising a compound of formula (I), as defined above, or a


    salt or a pharmaceutically acceptable solvate thereof, and at least one pharmaceutically acceptable excipient, for use in the treatment of neuropathic pain.
    Or formulated in another way, another aspect of the invention is a method for
    5 treatment of neuropathic pain in a patient in need of it comprising theadministration of a pharmaceutical composition comprising a compound of formula(I), as defined above, either a salt or a pharmaceutically solvateacceptable thereof, and at least one pharmaceutically acceptable excipient.
    The pharmaceutical composition whose use is part of the present invention can generally be administered by any route of administration, for example, orally, sublingually, rectally, nasally, ocularly, topically, or parenterally through the use of a injectable form, for example, intravenous, subcutaneous, intradermal, intraarticular, or intramuscular injections.
    This composition may be in any pharmaceutical form, adapted to the type of administration desired. The usual pharmaceutical forms and their mode of preparation are well known to the person skilled in the art and are described, for example, in the Remington Pharmaceutical Technology Manual, The Science and Practice of Pharmacy, Lippincott
    20 Williams & Wilkins, 21st Edition, 2015, [ISBN 0-683-306472].
    In one embodiment of the invention, the pharmaceutical composition is for oral administration. Pharmaceutical forms suitable for oral administration may be in liquid form, as solutions or suspensions, or in solid form, as tablets,
    25 capsules, powders, or granules, for example.
    In another embodiment of the invention, the pharmaceutical composition is for topical administration. The forms suitable for topical administration may be in liquid form
    or semi-solid, in the form of creams, lotions, or pastes, for example.
    In another embodiment of the invention, the pharmaceutical composition is for parenteral administration. The forms suitable for parenteral administration may be in the form of solutions, suspensions or emulsions, or in solid form, typically in powder form, suitable to be reconstituted with a liquid prior to its
    35 administration.


    The person skilled in the art will have no difficulty in formulating said composition with the help of pharmaceutically acceptable excipients, chosen according to the type of pharmaceutical form and the route of administration. The physicochemical characteristics of the main excipients,
    5 as well as the name of the commercial products under which they are marketed can be found, for example, in the book R.C. Rowe et al., Handbook of Pharmaceutical Excipients, Pharmaceutical Press, 6th Edition, 2009, [ISBN 978 0 85369 792 3].
    The composition whose use is part of the present invention comprises the compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, typically comprises a therapeutically effective amount of said compound.
    Said therapeutically effective amount, which is suitable for an effective treatment of neuropathic pain, may vary depending on various factors, such as the route of administration, the specific pathology to be treated and the severity thereof.
    In general, the therapeutically effective daily dose of the compounds of the present invention is between 0.01 mg / kg / day and 100 mg / kg / day, more preferably between 1 mg / kg / day and 30 mg / kg / day.
    20 This dose can be administered according to different dosages, adapted to each patient and for each specific pathology, and according to the route of administration and the pharmaceutical form used. Typically, a single daily administration may be used, or divided into two or more administrations per day. Eventually, they can also
    25 follow treatment guidelines with lower frequencies, lower than a daily dose.
    Examples
    The efficacy of the compounds of formula (I) in various experimental models of neuropathic pain was tested, as described below in Examples 1, 2, 3, 4 and 5. In
    In all cases, the compound chosen as representative of the compounds of formula (I) was the trisodium salt of 2-acetamido-2-deoxy-3-O- (β-D-glucopyranosyl uronic acid) -4,6-di -Sulfo-α-D-methyl glucopyranoside (compound Ic).
    Example 1 Efficacy of compound Ic in a mechanical allodynia model induced by capsaicin


    For this test, 6 groups of mice were used, with between 8 and 12 animals in each group. After allowing the animals to acclimatize for a while in the experimental chambers, a solution with 1 µg of capsaicin, or only solvent (phosphate buffered saline, PBS: phosphate buffered saline) was administered to the right hind leg. control. After 15 minutes of the injection, different mechanical stimuli were applied with a von Frey filament with a force of 0.5 g in a stesiometer, and the latency time values were recorded until the leg was removed. The maximum time of application of the mechanical stimulus was 50 seconds and each stimulus was applied 3 times, leaving a minimum interval of 30 seconds between each application, so that the average of the three measures was the value assigned for each animal for the time of latency until withdrawal.
    To evaluate the effect of compound Ic on the allodynia thus induced, said compound was administered by gastric probe dissolved in saline, 45 minutes before the test, in different doses (3, 10 and 30 mg / Kg). For comparative purposes, one group of animals was treated only with the vehicle (saline solution) and another group was treated with gabapentin at a dose of 40 mg / kg, as a positive control.
    To quantify the anti-allodynic effect, a value of 100% allodynia was assigned at the latency time of animals injected with capsaicin and without pharmacological treatment (treated only with the vehicle). The rest of the values were normalized with respect to this one.
    The results obtained are represented in the bar chart of Figure 1, where the percentage of allodynia is represented on the ordinate axis, and on the abscissa axis the various groups and treatments performed are represented: the first bar (Ctrl) represents the control that corresponds to mice without treatment and in which no allodynia was induced, injected only with the phosphate buffered saline; the second bar (Ic-0) represents the animals with 100% allodynia, that is, injected with capsaicin, and without treatment with any drug (only saline was administered); Ic-3, Ic-10 and Ic-30 bars represent the percentage of allodynia calculated for sensitized animals (injected with capsaicin) and treated with 3, 10 and 30 mg / Kg, respectively, of compound Ic; and the last bar (Gab) represents the percentage of allodynia obtained for sensitized animals (injected with capsaicin) and treated with 40 mg / kg of gabapentin. The data are means ± SEM (standard error of the mean) of at least 10 animals per experimental group (*** p <0.001 ANOVA and Dunett test).


    The compound Ic showed a remarkable antialodynic effect, increasing with the administered dose, so that with the highest dose tested, 30 mg / Kg (Ic-30 bar), a reduction in allodynia greater than 50% was obtained.
    Example 2 Efficacy of compound Ic in a model of mechanical allodynia produced by
    Ligation of the sciatic nerve For this test groups of rats with between 6 and 7 animals in each group were used. Mechanical allodynia was induced in the animals (except the control group) by chronic ligation of the sciatic nerve, and the so-induced allodynia was recorded after 7 days after surgery.
    Compound Ic was administered in various doses (3, 30 and 60 mg / kg), as well as only saline as a control, and gabapentin (40 mg / kg) as a positive comparator. The products were administered by gastric tube 45 minutes before the measurement of allodynia, which was quantified using von Frey filaments, according to the threshold of force necessary to cause the animal's leg to be removed.
    The results are summarized in Figure 2, where the ordinate axis represents half of the threshold force that must be applied to cause the leg to be removed (50% pain threshold, in grams, g) and on the axis The different groups and treatments performed are shown in bars. Thus, from left to right, the first bar represents the control group (Ctrl), that is, animals without allodynia, that is, not undergoing surgery and to which no treatment was administered; the second bar (Ic-0) corresponds to the group of animals with allodynia induced by sciatic nerve ligation, but without pharmacological treatment (they were administered only saline serum); the third bar (Gab) corresponds to the animals that had a sciatic nerve ligation, and were treated with the gabapentin comparator; while the last three bars (Ic-3, Ic-30 and Ic-60) correspond to animals also subjected to sciatic nerve ligation and treated with compound Ic, at different doses, of 3, 30 and 60 mg / Kg respectively. Data are means ± SEM (standard error of the mean) of at least 6 animals per experimental group (*** p <0.001 compared to the Ic-0 group; $$$ p <0.001 compared to the Ctrl group; ANOVA of one way followed by Tukey's post-hoc test).


    The results represented in Figure 2 confirm that the administration of the different doses studied of compound Ic were effective in reversing the allodynia induced in the present model. The antialodinic effect of the doses of 3 and 30 mg / Kg is remarkable, while with the higher dose of 60 mg / Kg, in addition to producing the total reversal of allodynia, it also achieved an analgesic effect.
    An analogous trial was performed, in which different doses of compound Ic (30, 60 and 120 mg / kg) and gabapentin (40 mg / kg) were administered, and the 50% pain threshold was measured at different times after administration. to evaluate the temporal evolution and the duration of the antialodynic effect. The results are shown in Figure 3, where the ordinate axis represents half of the threshold force that must be applied to cause the leg to be removed (50% pain threshold, in grams, g), while in The abscissa axis represents the time elapsed (in minutes) since the administration of each drug. The empty circles represent the animals treated with gabapentin (positive control), the solid circles represent the animals treated with 120 mg / kg of the compound Ic, the triangles represent the animals treated with 60 mg / kg of the compound Ic and the inverted triangles represent the animals treated with a dose of 30 mg / kg of compound Ic. Data are means ± SEM (standard error of the mean) of at least 7 animals per experimental group.
    Example 3 Efficacy of compound Ic in a neuropathic pain model induced by
    Chemotherapy (paclitaxel) In this trial groups of mice of between 7 and 12 animals were used per group, which were administered intraperitoneally a daily dose of paclitaxel of 2 mg / kg, for 5 consecutive days (except the control group ). The evaluation of induced mechanical allodynia was performed on day 10 after the first injection of paclitaxel, and was quantified using von Frey filaments, according to the threshold of force necessary to cause the animal's leg to be removed.
    To evaluate the ability of compound Ic to reverse paclitaxel-induced allodynia, a first baseline measure of the withdrawal force threshold of the paws of the animals was made, and then a single dose of the compound was administered orally and made a new measure after 45 minutes of administration.


    The results obtained are represented graphically in Figure 4, where the threshold force that is necessary to apply to cause the removal of the animal's leg, expressed as a percentage with respect to the control group, constituted by animals is represented on the ordinate axis. in which no allodynia was induced, and in the abscissa axis the different groups and treatments performed are represented. From left to right, the control group is represented first, without induction of allodynia (Ctrl), and then (A) the baseline measurement is performed on animals with paclitaxel-induced allodynia, before administering the treatment, which corresponds at the maximum value of induced allodynia. The treatments performed are shown below: Ic-0 (without treatment, only saline was administered), and Ic-7.5, Ic-15 and Ic-30 corresponding, respectively, to the administration of 7.5, 15 and 30 mg / kg of compound Ic. The data are means ± SEM (standard error of the mean) of at least 7 animals per experimental group (*** p <0.001, ** p <0.01; compared to the Ctrl group, one-way ANOVA and post test -hock of Dunnett).
    It was observed that the administration of increasing doses of compound Ic reversed paclitaxel-induced allodynia.
    A second trial was performed using this same model, according to which a daily oral dose of compound Ic was administered, for 5 consecutive days, co-administered with paclitaxel. Allodynia was evaluated on day 10 after the start of treatment.
    Figure 5 shows the results obtained in this test. In the ordinate axis the threshold force that is necessary to apply to cause the removal of the animal's leg (in grams, g) is represented, while in the abscissa axis the different groups and treatments are represented. In the first pair of bars the animals without any treatment (Ctrl) are compared with those that received paclitaxel together with saline, that is, they did not receive treatment with the compound Ic (Tax + Ic-0). In the second pair of bars the control group (Ctrl) is compared with the group of animals that were treated together with paclitaxel and 30 mg / Kg of the compound Ic (Tax + Ic-30). The data are means ± SEM (standard error of the mean) of at least 7 animals per experimental group (*** p <0.001 comparison with the Ctrl group, t-Student test).
    It was observed that compound Ic, co-administered with paclitaxel for 5 days, prevented the development of allodynia.


    EXAMPLE 4 Efficacy of compound Ic in a cold allodynia model In this assay, 16 mice were used which were administered 50 µl of a 1% carrageenan solution by subcutaneous injection into the plantar surface of one of the hind legs. After 3.5 hours after the injection, 9 of the animals were administered 60 mg / kg of compound Ic orally, while the remaining 7 (control group) were given only the vehicle (saline). 45 minutes after said treatment, cold sensitivity was quantified by administering a drop of acetone on the plantar surface of the two hind legs, that is, the ipsilateral one (the same one where the carrageenan was injected) and the contralateral one (the leg non-sensitized back), and then the leg licking time was measured for a period of 5 minutes after the administration of acetone, regardless of the behavior during the first 15 seconds, since most animals had a reaction Initial to application.
    The test results are shown in Figure 6, where the leg licking time is represented in the ordinate axis (in seconds), and the different groups and treatments are represented in the abscissa axis. The first pair of bars corresponds to the group of control animals and the second pair of bars corresponds to animals treated with 60 mg / Kg of compound Ic. In both cases, the bar on the left (striped) represents the results for the sensitized hind leg (ipsilateral) and the one on the right (empty) represents the results for the other, non-sensitized (contralateral) hind leg. In all cases, the data are means ± SEM (standard error of the mean) for the 7 or 9 animals, respectively, of each group (** p <0.01 compared with Ctrl white bar, two-way paired ttest ; ### p <0.001 compared to the gray bar of the Ctrl, two-way unpaired t-test).
    A strong cold allodynia effect was observed in the carragenin sensitized hind leg (ipsilateral), while this effect was completely reversed in animals treated with compound Ic, as can be seen in the graph when comparing the results for the ipsilateral leg (striped bars) between control animals (Ctrl) and animals treated with compound Ic (Ic-60).
    Example 5 Efficacy of compound Ic in a model of allodynia due to diabetes induced by
    Streptozotocin injection Diabetes was induced in rats by intraperitoneal injection of 60 mg / kg of streptozotocin for five consecutive days and the evaluation of allodynia was carried out on day 25 after


    The first injection. Animals whose plasma glucose value was not greater than 250 mg / ml were discarded. For the evaluation of the effect of compound Ic on allodynia thus induced by diabetes, five groups of animals were used with at least 7 animals in each group, and allodynia was quantified using von Frey filaments, according to the threshold
    5 of force necessary to cause the animal's leg to be removed.
    Compound Ic was administered orally to the animals by gastric tube, in a single administration and allodynia was measured in each animal immediately before administration and 45 minutes after administration. The first group of animals is
    10 treated with a dose of 3 mg / kg of compound Ic, the second group with a dose of 30 mg / kg of compound Ic and the third, with a dose of 30 mg / kg of the same compound.
    The results are summarized in Figure 7, where the ordinate axis represents half of the threshold force that must be applied to cause the removal of leg 15 (threshold 50% of pain, in grams, g) and in the The abscissa axis represents the different groups and treatments performed in bars. From left to right, the first bar corresponds to the group of animals before starting the experimental protocol, before developing diabetes. Next, the disgusting pair of bars corresponds to the data obtained in animals at day 25 after the first streptozotocin injection 20 before, vertical stripes, and then, horizontal stripes, of the administration of a control saline solution. Next, the following three bars represent the values obtained after the administration of the three doses of compound Ic; 3, 10 and 30 mg / kg Finally, the white bar represents the values obtained after administration of the pregabalin compound at 40 mg / kg that acts as a positive control of the experiment. In all 25 cases, the data are means ± SEM (standard error of the mean) for the 7-10 animals of each group (** p <0.01. *** p <0.001 compared to the group of animals administered with saline; gray bar with horizontal stripes. Two-way unpaired T-test) .The results shown in Figure 7 confirm that both doses of compound Ic, 10 and 30 mg / kg, were effective in reversing the allodynia induced herein. model. Especially
    30 for the dose of 30 mg / kg where the differences were statistically significant.

    权利要求:
    Claims (10)
    [1]
    1.-Use of a compound of formula (I):
    5 where:
    - R1 is selected from hydrogen, linear or branched C1-C4 alkyl, phenylalkyl of
    less than 10 carbon atoms and COCH3;
    - R2 is selected from hydrogen, COCH3 and SO3Y;
    - R3 is selected from hydrogen, linear or branched C1-C4 alkyl, phenylalkyl of less than 10 carbon atoms, COCH3 and COPh, where Ph is phenyl;
    - G is selected from COOR4 and COOY;
    - A and B are selected, independently from each other, from hydrogen, SO3H, SO3Y
    and COCH3;
    wherein necessarily A or B is either SO3H, or SO3Y, 15 R4 is selected from hydrogen, C1-C2 alkyl and arylalkyl of less than 16 atoms of
    carbon e
    And it is an organic or inorganic cation;
    or a pharmaceutically acceptable salt or solvate thereof, for the preparation of a medicament for the treatment of neuropathic pain. twenty
    [2]
    2. Use according to claim 1, characterized in that:
    - R1 is selected from hydrogen and linear C1-C4 alkyl, and
    - G is selected from –COOR4 and –COOY, where R4 is hydrogen or C1-C2 alkyl
    and Y is an inorganic cation.
    3. Use according to claim 2, characterized in that R1 is hydrogen, R2 is COCH3 and R3 is hydrogen.
    [4]
    4. Use according to claim 2, characterized in that R1 is methyl, R2 is COCH3 and R3 is hydrogen.

    [5]
    5. Use according to any one of claims 3 or 4, characterized in that A is hydrogen, B is SO3Y and G is -COOY, wherein Y is an inorganic cation.
    [6]
    6. Use according to any of claims 3 or 4, characterized in that A is SO3Y, B 5 is hydrogen, and G is -COOY, wherein Y is an inorganic cation.
    [7]
    7. Use according to any of claims 3 or 4, characterized in that A and B are SO3Y and G is -COOY, wherein Y is an inorganic cation.
    8. Use according to claim 1, characterized in that the compound of formula (I) is selected from the group consisting of the following compounds:
    [9]
    9. Use according to claim 1, characterized in that the compound of formula (I) is:

    [10]
    10. Use of a pharmaceutical composition comprising a compound of formula (I) as defined in any one of claims 1 to 9, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient, for the preparation of a medication for the treatment of neuropathic pain.
    [11]
    11. Use according to any of claims 1 to 10, characterized in that the neuropathic pain is chosen from: diabetic neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathy, HIV-associated neuropathy, rheumatoid arthritis-associated neuropathy, osteoarthritis-associated neuropathy , fibromyalgia-associated neuropathy, neuralgia
    10 trigeminal, glossopharyngeal neuralgia, sphenopalatine ganglion neuralgia, vidian neuralgia, persistent idiopathic facial pain, primary atypical facial neuralgia, phantom limb associated pain, post-stroke stroke syndrome, post-surgical pain syndrome, multiple sclerosis pain and pain spinal cord injury.
    12. 12. Use according to claim 11, characterized in that the neuropathic pain is chosen from: diabetic neuropathy, post-herpetic neuralgia, neuropathic pain due to chemotherapy and fibromyalgia-associated neuropathy.
    [13]
    13. Use according to any of claims 1 to 12, characterized in that the
    20 treatment of neuropathic pain refers to reversing or preventing the symptoms of mechanical allodynia or cold allodynia.

    DRAWINGS
    Figure 1
    Figure 2

    Figure 3
    Figure 4 29

    Figure 5
    Figure 6

    Figure 7
    类似技术:
    公开号 | 公开日 | 专利标题
    Tascιoglu et al.2003|Efficacy of intra-articular sodium hyaluronate in the treatment of knee osteoarthritis
    ES2287039T3|2007-12-16|A PIRROLIDINACETAMIDE DERIVATIVE FOR THE TREATMENT OF CHRONIC OR NEUROPATHIC PAIN.
    Schmidt2001|Alvimopan | is a novel peripheral opioid antagonist
    ES2237461T3|2005-08-01|USE OF RETIGABINE FOR THE TREATMENT OF NEUROPATIC PAIN.
    ES2577930T3|2016-07-19|Triazine derivatives to delay the onset of type 1 diabetes
    AR082150A1|2012-11-14|N-ETIL-N-Phenyl-1,2-DIHIDRO-4-HYDROXI-5-CHLORINE-1-METHYL-2-OXOQUINOLIN-3-CARBOXAMIDE DEUTERADA, SALTS AND USES OF THE SAME, TREATMENT METHOD, COMPOUND BLEND, COMPOSITION PHARMACEUTICS, PREPARATION PROCESS, ENRICHED COMPOUND WITH DEUTERIO
    Papanas et al.2016|Emerging drugs for diabetic peripheral neuropathy and neuropathic pain
    CO6241170A2|2011-01-20|ADMINISTRATION OF ANTISENTIDE OLIGONUCLEOTIDES COMPLEMENTARY TO HUMAN APOLIPOPROTEIN B
    Shindler et al.1984|Domperidone and levodopa in Parkinson's disease.
    ES2536631T3|2015-05-27|Use of dimiracetam in the treatment of chronic pain
    EP2614821B1|2016-11-09|Pharmaceutical composition for treating anxiety disorder, containing n-acetyl-l-cysteine or derivative thereof
    TWI612965B|2018-02-01|Use of hyaluronic acid and pharmacetical composition for inhibiting pain
    Lagos2014|Clinical applications of paralytic shellfish poisoning toxins
    ES2684097B1|2019-07-04|Sulfated disaccharides for the treatment of neuropathic pain
    Strumper et al.2004|Antidepressants as long-acting local anesthetics
    ES2694352T3|2018-12-20|Use of an opioid receptor antagonist with kappa activity, and vortioxetine for the treatment of depressive disorder with melancholic features
    Honda et al.2015|The inhibitory effect of locally injected dexmedetomidine on carrageenan-induced nociception in rats
    ES2769780T3|2020-06-29|Novel treatments for attention and cognitive disorders and for dementia associated with a neurodegenerative disorder
    US20210236594A1|2021-08-05|Methods for improving frailty and aging
    CA2942641A1|2014-10-02|Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor
    PT2724722T|2017-03-14|Method of restoring the incretin effect
    WO2013088410A1|2013-06-20|Antineuritic pharmaceutical combination and compositions
    US20140162958A1|2014-06-12|Copolymer-1 Composition and Methods of Use
    Ravishankar et al.2011|Sublingual piroxicam in migraine without aura
    McCleane2009|Pain management: expanding the pharmacological options
    同族专利:
    公开号 | 公开日
    US11046722B2|2021-06-29|
    ES2684097B1|2019-07-04|
    EP3600335A1|2020-02-05|
    WO2018177693A1|2018-10-04|
    US20200102339A1|2020-04-02|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    ES2167251A1|2000-07-13|2002-05-01|Bioiberica|Novel disaccharides with anti-arthritic action|
    ES2327480A1|2007-06-15|2009-10-29|Bioiberica, S.A.|Disaccharides for the treatment of tendons, ligaments and bones|
    ES2364683A1|2009-12-29|2011-09-12|Bioibérica S.A.|Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases|
    WO2005118609A2|2004-05-26|2005-12-15|California Institute Of Technology|Small molecule stimulators of neuronal growth|
    法律状态:
    2018-10-01| BA2A| Patent application published|Ref document number: 2684097 Country of ref document: ES Kind code of ref document: A1 Effective date: 20181001 |
    2019-07-04| FG2A| Definitive protection|Ref document number: 2684097 Country of ref document: ES Kind code of ref document: B1 Effective date: 20190704 |
    优先权:
    申请号 | 申请日 | 专利标题
    ES201730458A|ES2684097B1|2017-03-29|2017-03-29|Sulfated disaccharides for the treatment of neuropathic pain|ES201730458A| ES2684097B1|2017-03-29|2017-03-29|Sulfated disaccharides for the treatment of neuropathic pain|
    US16/499,600| US11046722B2|2017-03-29|2018-03-06|Sulphated disaccharides for the treatment of neuropathic pain|
    EP18709003.0A| EP3600335A1|2017-03-29|2018-03-06|Sulphated disaccharides for the treatment of neuropathic pain|
    PCT/EP2018/055430| WO2018177693A1|2017-03-29|2018-03-06|Sulphated disaccharides for the treatment of neuropathic pain|
    [返回顶部]